索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]于甜乐,刘宏.CD147 在心肌缺血再灌注损伤中的作用机制[J].国际心血管病杂志,2022,06:333-336.
点击复制

CD147 在心肌缺血再灌注损伤中的作用机制 (PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2022年06期
页码:
333-336
栏目:
综述
出版日期:
2022-12-20

文章信息/Info

Title:
-
作者:
于甜乐; 刘宏
671000 大理大学临床医学院（于甜乐）；671000 大 理大学第一附属医院心血管内科，云南省跨高原心血管疾病防治工 程研究中心，大理大学跨高原心血管疾病防治研究所（刘宏）
Author(s):
-
关键词:
CD147 ; 心肌缺血再灌注损伤; 作用机制
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2022.06.004
文献标识码:
-
摘要:
急性心肌梗死再灌注在治疗时会发生再灌注损伤，导致不良的心血管后果，严 重影响急性心肌梗死患者的治疗效果。CD147 与多因子结合参与心肌梗死的发病机制，且在 心肌缺血再灌注中表达明显异常。抑制CD147 或其相关配体可改善再灌注损伤，CD147 有 望成为新的治疗靶点。该文介绍CD147 在心肌缺血再灌注损伤中的作用机制。
Abstract:
-

参考文献/References

[1] Panagiotou A, Trendelenburg M, Osthoff M. The Lectin pathway of complement in myocardial ischemia/reperfusion injury-review of its significance and the potential impact of therapeutic interference by C1 esterase inhibitor[J]. Front Immunol, 2018, 9:1151.
[2] Pennings GJ, Kritharides L. CD147 in cardiovascular disease and thrombosis[J]. Semin Thromb Hemost, 2014, 40(7):747- 755.
[3] Seizer P, Gawaz M, May AE. Cyclophilin A and EMMPRIN (CD147) in cardiovascular diseases[J]. Cardiovasc Res, 2014, 102(1):17-23.
[4] Akkus MN, Ormam A, Seyis S, et al. Plasma EMMPRIN levels in acute myocardial infarction and stable coronary artery disease[J]. Clin Invest Med, 2016, 39(3):79-87.
[5] Seizer P, Ochmann C, Sch?nberger T, et al. Disrupting the EMMPRIN(CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion[J]. Arterioscler Thromb Vasc Biol, 2011, 31(6):1377-1386.
[6] Shi Y, Yan W, Lin Q, et al. Icariin influences cardiac remodeling following myocardial infarction by regulating the CD147/MMP-9 pathway[J]. J Int Med Res, 2018, 46(6):2371- 2385.
[7] Lv X, Lu P, Hu Y, et al. MiR-346 inhibited apoptosis against myocardial ischemia-reperfusion injury via targeting bax in rats[J]. Drug Des Devel Ther, 2020, 14:895-905.
[8] Frank A, Bonney M, Bonney S, et al. Myocardial ischemia reperfusion injury:from basic science to clinical bedside[J]. Semin Cardiothorac Vasc Anesth, 2012, 16(3):123-132.
[9] Nishikata R, Kato N, Hiraiwa K. Oxidative stress may be involved in distant organ failure in tourniquet shock model mice[J]. Leg Med (Tokyo), 2014, 16(2):70-75.
[10] Fr?hlich GM, Meier P, White SK, et al. Myocardial reperfusion injury: looking beyond primary PCI[J]. Eur Heart J, 2013, 34(23):1714-1722.
[11] Davidson B, Goldberg I, Berner A, et al. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma[J]. Clin Exp Metastasis, 2003, 20(2):161-169.
[12] Lian C, Guo Y, Zhang J, et al. Targeting CD147 is a novel strategy for antitumor therapy[J]. Curr Pharm Des, 2017, 23(29):4410-4421.
[13] Patrizz A, Doran SJ, Chauhan A, et al. EMMPRIN/CD147 plays a detrimental role in clinical and experimental ischemic stroke[J]. Aging (Albany NY), 2020, 12(6):5121-5139.
[14] Liehn EA, Piccinini AM, Koenen RR, et al. A new monocyte chemotactic protein-1/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice[J]. J Am Coll Cardiol, 2010, 56(22):1847-1857.
[15] Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling[J]. Nat Rev Cardiol, 2014, 11(5): 255-265.
[16] Zhu X, Song Z, Zhang S, et al. CD147: a novel modulator of inflammatory and immune disorders[J]. Curr Med Chem, 2014, 21(19):2138-2145.
[17] Tarin C, Lavin B, Gomez M, et al. The extracellular matrix metalloproteinase inducer EMMPRIN is a target of nitric oxide in myocardial ischemia/reperfusion[J]. Free Radic Biol Med, 2011, 51(2):387-395.
[18] Cuadrado I, Castejon B, Martin AM, et al. Nitric oxide induces cardiac protection by preventing extracellular matrix degradation through the complex Caveolin-3/EMMPRIN in cardiac myocytes[J]. PLoS One, 2016, 11(9):e0162912.
[19] Yuan W, Ge H, He B. Pro-inflammatory activities induced by CyPA-EMMPRIN interaction in monocytes[J]. Atherosclerosis, 2010, 213(2):415-421.
[20] Yurchenko V, Constant S, Eisenmesser E, et al. Cyclophilin- CD147 interactions: a new target for anti-inflammatory therapeutics[J]. Clin Exp Immunol, 2010, 160(3):305-317.
[21] Jin R, Liu S, Wang M, et al. Inhibition of CD147 attenuates stroke-associated pneumonia through modulating lung immune response in mice[J]. Front Neurol, 2019, 10:853.
[22] Wang CH, Dai JY, Wang L, et al. Expression of CD147 (EMMPRIN) on neutrophils in rheumatoid arthritis enhances chemotaxis, matrix metalloproteinase production and invasiveness of synoviocytes[J]. J Cell Mol Med, 2011, 15(4): 850-860.
[23] Su H, Yang Y. The roles of CyPA and CD147 in cardiac remodelling[J]. Exp Mol Pathol, 2018, 104(3):222-226.
[24] Rodríguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics[J]. Biochim Biophys Acta, 2010, 1803(1):39-54.
[25] Fernández-Velasco M, González-Ramos S, Boscá L. Involvement of monocytes/macrophages as key factors in the development and progression of cardiovascular diseases[J]. Biochem J, 2014, 458(2):187-193.
[26] Adair-Kirk TL, Senior RM. Fragments of extracellular matrix as mediators of inflammation[J]. Int J Biochem Cell Biol, 2008, 40(6/7):1101-1110.
[27] Radosinska J, Barancik M, Vrbjar N. Heart failure and role of circulating MMP-2 and MMP-9[J]. Panminerva Med, 2017, 59(3):241-253.
[28] Lima B, Forrester MT, Hess DT, et al. S-nitrosylation in cardiovascular signaling[J]. Circ Res, 2010, 106(4): 633-646.
[29] Foster MW, McMahon TJ, Stamler JS. S-nitrosylation in health and disease[J]. Trends Mol Med, 2003, 9(4):160-168.
[30] Atar S, Ye Y, Lin Y, et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2[J]. Am J Physiol Heart Circ Physiol, 2006, 290(5):H1960-H1968.
[31] Hallstr?m S, Franz M, Gasser H, et al. S-nitroso human serum albumin reduces ischaemia/reperfusion injury in the pig heart after unprotected warm ischaemia[J]. Cardiovasc Res, 2008, 77(3):506-514.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金(81760085) ；云南省教育厅科研基金 （2020Y0564）
通信作者：刘宏， E-mail：daliliuhong@163.com
更新日期/Last Update: 2022-12-20